报告期内，公司为全球320余家客户提供小分子原料药服务，引入新客户40家。尽管国内仿制药制剂 CDMO市场需求承压，公司通过内部精益运营体系优化，有效应对行业挑战，达成小分子制剂业务减亏 目标。制剂团队服务订单客户数106家，服务订单项目数145个，引入新客户13家，新签订单约6398万 元。 基因细胞治疗业务阶段性达成减亏目标。报告期内，博腾生物服务订单客户51家，服务订单项目89个； 引入新客户19家，新项目34个，新签订单5255万元。在市场端取得多个突破：获得首个韩国客户订单； 获得首个端到端的iPSC IND订单；获得首个CIK细胞IND订单。在交付端，博腾生物助力客户取得2个 IND批件，均为"零发补"。 此外，公司新分子业务新签订单4186万元，为38家客户的67个项目提供服务，涵盖临床早期、IND、临 床三期和NDA等不同阶段。上半年，新分子业务线获得海外双载荷(Dual-Payload)ADC IND整包项目， 实现40个项目的阶段性交付，涵盖RDC、AOC、APC等复杂项目类型。 截至报告期末，博腾股份累计服务客户1300余家，拥有超过4600个项目的成功交付记录，服务终端药物 包括抗病毒 ...

Hong Kong Market Overview - The Hang Seng Index closed at 24,072, down 0.87% for the day but up 20% year-to-date[3] - The Hang Seng China Enterprises Index fell 0.96% to 8,678, with a year-to-date increase of 19.05%[3] - The Hang Seng Tech Index decreased by 0.72% to 5,303, showing an 18.68% rise for the year[3] - In June, the Hang Seng Index, China Enterprises Index, and Tech Index rose by 3.36%, 2.92%, and 2.56% respectively[10] US Market Performance - The Dow Jones Industrial Average increased by 0.91% to 44,495, with a year-to-date gain of 4.59%[3] - The S&P 500 Index fell by 0.11% to 6,198, up 5.38% year-to-date[3] - The Nasdaq Composite dropped 0.82% to 20,203, with a year-to-date increase of 4.62%[3] - Major tech stocks showed mixed results, with Nvidia down 2.97% and Apple up 1.29%[10] Sector Trends - In the US, all sectors except Technology, Communications, and Semiconductors saw gains, with Materials up 2.59% and Healthcare up 1.42%[10] - In Hong Kong, new consumption and stablecoin concepts gained traction, while gold and precious metal stocks faced declines[10] Notable Stock Movements - Xiaomi and NetEase rose over 1%, while Meituan and Alibaba fell over 2%[10] - In the US, Tesla dropped 5.34%, while Amazon and Berkshire Hathaway saw slight increases[10] - Chinese electric vehicle manufacturers showed varied performance, with Li Auto down 1.03% and XPeng up 2.13%[11]

Market Overview - The Hong Kong stock market experienced a collective decline on June 12, with the Hang Seng Index falling by 1.36%, the Hang Seng China Enterprises Index down by 1.53%, and the Hang Seng Tech Index decreasing by 2.2% [1] - Various sectors, including short video, cloud computing, and tech stocks, saw significant drops, with Kuaishou-W down 5.87% and Alibaba-W down 3.21% [1] Sector Performance - The consumer sector faced pressure, with notable declines in beer, sports goods, and airline stocks. Budweiser APAC dropped 6.39%, while Meituan-W fell by 1.95% [1] - The automotive industry, including lithium batteries and smart driving concepts, also saw a downturn, with China Graphite down 12.36% and Xpeng Motors-W down 6.66% [2] - Chip and robotics stocks experienced declines, with Horizon Robotics-W down 3.9% and SMIC down 2.04% [2] Gainers - Pharmaceutical stocks showed resilience, with China Biologic Products rising by 19.29% due to anticipated significant business developments [3] - Other biopharmaceutical companies like Junshi Biosciences and Zai Lab also saw substantial gains, with increases of 12.35% and 8.65% respectively [3] Gold and Precious Metals - Gold and precious metals stocks rose, driven by global gold purchasing trends and rising gold prices. Zijin Mining increased by 4.93% [4] - The global demand for gold as a reserve asset has surged, with central banks increasing their gold holdings amid geopolitical tensions [4] Notable Stocks - Cloudfin Financial, associated with Ant Group, surged by 54.24% following reports of plans to apply for stablecoin licenses in Singapore and Hong Kong [4] - Jiuyuan Gene saw a remarkable increase of 43.73%, marking its fourth consecutive day of gains [5]

Core Insights - The CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) sectors are crucial in advancing innovative drugs from laboratory to clinical application and large-scale production, with Chinese companies gaining significant market share due to enhanced technical capabilities and cost advantages [1][2]. Group 1: Strategic Opportunities in CXO - The CXO sector in China has experienced rapid growth over the past decade, evolving through four development stages, with a significant acceleration post-2015 due to increased demand for innovative drug development and the transfer of overseas industrial chains [2][3]. - The COVID-19 pandemic in 2020 catalyzed the upgrade of China's CXO industry, leading to a surge in participation in the global innovative drug supply chain [3]. Group 2: Growing Demand for Outsourcing in the Pharmaceutical Industry - The number of new drug registration clinical trials in China has been increasing annually, with a compound annual growth rate (CAGR) of 15% from 2019 to 2024, rising from 2,385 trials in 2019 to 4,884 in 2024 [4]. - The number of first-class new drugs listed in China has grown from 18 in 2020 to 49 in 2024, reflecting a CAGR of 28.4%, indicating a sustained upward trend in innovation capabilities [6]. Group 3: MAH System and Business Opportunities - The implementation of the MAH (Marketing Authorization Holder) system has separated drug production and marketing licenses, significantly boosting the CDMO market, with the number of B certificate enterprises increasing from 140 in 2021 to 1,349 by the end of 2024, a growth rate of 23% [10]. Group 4: Market Growth Rates - China's CRO market is projected to grow at a CAGR of 20.4%, increasing from 388 billion RMB in 2018 to 1,183 billion RMB in 2024, with expectations to reach 1,923 billion RMB by 2027 [12][14]. - The CDMO market in China is expected to grow at a CAGR of 37.8%, from 132 billion RMB in 2017 to 1,246 billion RMB in 2024, with projections to reach 3,559 billion RMB by 2030 [16][18]. Group 5: Rankings of CRO and CDMO Companies - The 2024 rankings of Chinese CRO companies include top-tier firms such as WuXi Biologics, Kanglong Chemical, and Tigermed, while the second tier features companies like Yino Science and Kingsray Biotech [22]. - The leading CDMO companies in 2024 include WuXi AppTec, Kelun Pharmaceutical, and WuXi Biologics, with a second tier comprising companies like Notch Biotech and Haier Pharmaceutical [24]. Group 6: Conclusion - Chinese CRO and CDMO companies have established comprehensive service capabilities across the pharmaceutical industry chain, transitioning from "Chinese service providers" to "global innovation partners," with a focus on technological innovation and compliance [26][27].